Efficacy and Safety of Alirocumab in Statin-Intolerant Patients: Design of ODYSSEY ALTERNATIVE

This paper reported the design of ODYSSEY ALTERNATIVE — the first rigorously controlled trial of a PCSK9 inhibitor specifically in patients with confirmed statin intolerance, a group underserved by conventional lipid management.

The trial’s methodological innovation was its approach to statin intolerance confirmation. Rather than relying on patient self-report, ODYSSEY ALTERNATIVE required a structured run-in phase with statin rechallenge under blinded conditions — ensuring that enrolled patients had genuine statin intolerance rather than statin aversion. The comparator was ezetimibe rather than placebo, providing a clinically meaningful active control.

As a design paper, results were pending at publication. Its significance is primarily methodological: it established a rigorous phenotyping standard for statin intolerance in clinical trials and provided a framework for evaluating alternative LDL-lowering approaches in this population.

We rate the evidence limited — a design paper without outcome data. The clinical significance reflects the importance of the research question (PCSK9 inhibitors for statin-intolerant patients), not the evidence content of the article itself.